MRD-positive AML Clinical Study

NCT07131059 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

120

Enrollment

OTHER

Sponsor class

Conditions

AML, Adult

Interventions

DRUG: Ivosidenib
DRUG: Gilteritinib
DRUG: Venetoclax
DRUG: Avapritinib
DRUG: Daunorubicin
DRUG: Cytarabine
DRUG: Idarubicin
DRUG: MTZ
DRUG: HHT
DRUG: Azacitidine

Sponsor

Institute of Hematology & Blood Diseases Hospital, China